Buckle up AbbVie, Amgen: Biohaven's oral CGRP drug is gaining traction in migraine, doctors’ survey shows

With recent FDA approvals, the race for supremacy in migraine treatment is heating up among oral CGRP inhibitors, and a doctors’ survey is offering an early look at the winners.

Biohaven’s Nurtec ODT is pulling away from AbbVie’s Ubrelvy in the acute treatment of migraine, Piper Sandler analyst Christopher Raymond noted based on a survey of 99 U.S. primary care doctors. In the migraine prevention field, Nurtec and AbbVie’s newly approved Qulipta could pressure the growth potential of their injectable peers, the survey showed.